Serum vitamin d levels and polycystic ovary syndrome: A systematic review and meta-analysis

Nutrients

Volumn 7, Issue 6, 2015, Pages 4555-4577

  He, Chunla ^a   Lin, Zhoumeng ^b   Robb, Sara Wagner ^a   Ezeamama, Amara E ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

Metabolic and endocrine disorders; Polycystic ovary syndrome; Systematic review and meta analysis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANDROGEN; CALCITRIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; VITAMIN D; GLUCOSE BLOOD LEVEL;

BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DATA EXTRACTION; DYSGLYCEMIA; HUMAN; INSULIN RESISTANCE; INTERVENTION STUDY; MEDICAL LITERATURE; META ANALYSIS; METABOLIC DISORDER; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PUBLICATION; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; BLOOD; DIETARY SUPPLEMENT; FACTUAL DATABASE; FEMALE; GLUCOSE BLOOD LEVEL; METABOLIC SYNDROME X; METABOLISM; OBSERVATIONAL STUDY; POLYCYSTIC OVARY SYNDROME;

BLOOD GLUCOSE; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBSERVATIONAL STUDIES AS TOPIC; POLYCYSTIC OVARY SYNDROME; VITAMIN D;

EID: 84930942211     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7064555     Document Type: Review

References (87)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (pcos). Hum. Reprod.2004, 19, 41–47
2. Asuncion, M.; Calvo, R.M.; San Millan, J.L.; Sancho, J.; Avila, S.; Escobar-Morreale, H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from spain. J. Clin. Endocrinol. Metab.2000, 85, 2434–2438
3. Diamanti-Kandarakis, E.; Kouli, C.R.; Bergiele, A.T.; Filandra, F.A.; Tsianateli, T.C.; Spina, G.G.; Zapanti, E.D.; Bartzis, M.I. A survey of the polycystic ovary syndrome in the greek island of lesbos: Hormonal and metabolic profile. J. Clin. Endocrinol. Metab.1999, 84, 4006–4011
4. Azziz, R.; Woods, K.S.; Reyna, R.; Key, T.J.; Knochenhauer, E.S.; Yildiz, B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab.2004, 89, 2745–2749
5. March, W.A.; Moore, V.M.; Willson, K.J.; Phillips, D.I.; Norman, R.J.; Davies, M.J. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod.2010, 25, 544–551
6. Grulet, H.; Hecart, A.C.; Delemer, B.; Gross, A.; Sulmont, V.; Leutenegger, M.; Caron, J. Roles of lh and insulin resistance in lean and obese polycystic ovary syndrome. Clin. Endocrinol.1993, 38, 621–626
7. Diamanti-Kandarakis, E.; Dunaif, A. New perspectives in polycystic ovary syndrome. Trends Endocrinol. Metab.1996, 7, 267–271
8. Dunaif, A.; Finegood, D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab.1996, 81, 942–947
9. Alemzadeh, R.; Kansra, A.R. New adolescent polycystic ovary syndrome perspectives. Minerva Pediatr. 2011, 63, 35–47
10. Legro, R.S.; Kunselman, A.R.; Dunaif, A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med.2001, 111, 607–613
11. Morin-Papunen, L.C.; Vauhkonen, I.; Koivunen, R.M.; Ruokonen, A.; Tapanainen, J.S. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum. Reprod.2000, 15, 1266–1274
12. Wild, R.A.; Rizzo, M.; Clifton, S.; Carmina, E. Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertil. Steril.2011, 95, 1073–1079
13. Forrest, K.Y.; Stuhldreher, W.L. Prevalence and correlates of vitamin d deficiency in us adults. Nutr. Res.2011, 31, 48–54
14. Hovsepian, S.; Amini, M.; Aminorroaya, A.; Amini, P.; Iraj, B. Prevalence of vitamin d deficiency among adult population of Isfahan city, Iran. J. Health Popul. Nutr.2011, 29, 149–155
15. Tangpricha, V.; Pearce, E.N.; Chen, T.C.; Holick, M.F. Vitamin d insufficiency among free-living healthy young adults. Am. J. Med.2002, 112, 659–662
16. Thomson, R.L.; Spedding, S.; Buckley, J.D. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin. Endocrinol.2012, 77, 343–350
17. De Groot, P.C.; Dekkers, O.M.; Romijn, J.A.; Dieben, S.W.; Helmerhorst, F.M. Pcos, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis. Hum. Reprod. Update 2011, 17, 495–500
18. Khan, H.; Kunutsor, S.; Franco, O.H.; Chowdhury, R. Vitamin D, type 2 diabetes and other metabolic outcomes: A systematic review and meta-analysis of prospective studies. Proc. Nutr. Soc. 2013, 72, 89–97
19. Song, Y.; Wang, L.; Pittas, A.G.; Del Gobbo, L.C.; Zhang, C.; Manson, J.E.; Hu, F.B. Blood 25-hydroxy vitamin d levels and incident type 2 diabetes: A meta-analysis of prospective studies. Diabetes Care 2013, 36, 1422–1428
20. Verdoia, M.; Schaffer, A.; Sartori, C.; Barbieri, L.; Cassetti, E.; Marino, P.; Galasso, G.; De Luca, G. Vitamin D deficiency is independently associated with the extent of coronary artery disease. Eur. J. Clin. Investig. 2014, 44, 634–642
21. Krul-Poel, Y.H.; Snackey, C.; Louwers, Y.; Lips, P.; Lambalk, C.B.; Laven, J.S.; Simsek, S. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: A systematic review. Eur. J. Endocrinol.2013, 169, 853–865
22. Wehr, E.; Pilz, S.; Schweighofer, N.; Giuliani, A.; Kopera, D.; Pieber, T.R.; Obermayer-Pietsch, B. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur. J. Endocrinol.2009, 161, 575–582
23. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med.2007, 357, 266–281
24. Ramagopalan, S.V.; Heger, A.; Berlanga, A.J.; Maugeri, N.J.; Lincoln, M.R.; Burrell, A.; Handunnetthi, L.; Handel, A.E.; Disanto, G.; Orton, S.M.; et al. A chip-seq defined genome-wide map of vitamin d receptor binding: Associations with disease and evolution. Genome Res. 2010, 20, 1352–1360
25. Dobnig, H.; Pilz, S.; Scharnagl, H.; Renner, W.; Seelhorst, U.; Wellnitz, B.; Kinkeldei, J.; Boehm, B.O.; Weihrauch, G.; Maerz, W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med.2008, 168, 1340–1349
26. Freedman, D.M.; Looker, A.C.; Chang, S.C.; Graubard, B.I. Prospective study of serum vitamin D and cancer mortality in the united states. J. Natl. Cancer Inst.2007, 99, 1594–1602
27. Zittermann, A.; Schleithoff, S.S.; Tenderich, G.; Berthold, H.K.; Korfer, R.; Stehle, P. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J. Am. Coll. Cardiol.2003, 41, 105–112
28. Teegarden, D.; Donkin, S.S. Vitamin D: Emerging new roles in insulin sensitivity. Nutr. Res. Rev.2009, 22, 82–92
29. Plymate, S.R.; Matej, L.A.; Jones, R.E.; Friedl, K.E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J. Clin. Endocrinol. Metabol.1988, 67, 460–464
30. Haffner, S.M.; Stern, M.P.; Mitchell, B.D.; Hazuda, H.P.; Patterson, J.K. Incidence of type II diabetes in mexican americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes1990, 39, 283–288
31. Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia2000, 43, 148–155
32. Lillioja, S.; Mott, D.M.; Spraul, M.; Ferraro, R.; Foley, J.E.; Ravussin, E.; Knowler, W.C.; Bennett, P.H.; Bogardus, C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of pima indians. N. Engl. J. Med. 1993, 329, 1988–1992
33. Ruige, J.B.; Assendelft, W.J.; Dekker, J.M.; Kostense, P.J.; Heine, R.J.; Bouter, L.M. Insulin and risk of cardiovascular disease: A meta-analysis. Circulation 1998, 97, 996–1001
34. Rutter, M.K.; Meigs, J.B.; Sullivan, L.M.; D’Agostino, R.B.; Wilson, P.W. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the framingham offspring study. Diabetes2005, 54, 3252–3257
35. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. PLoS Med. 2009, 6, e1000097
36. Stroup, D.F.; Berlin, J.A.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.; Thacker, S.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA2000, 283, 2008–2012
37. Hartling, L.; Milne, A.; Hamm, M.P.; Vandermeer, B.; Ansari, M.; Tsertsvadze, A.; Dryden, D.M. Testing the newcastle ottawa scale showed low reliability between individual reviewers. J. Clin. Epidemiol.2013, 66, 982–993
38. Juni, P.; Altman, D.G.; Egger, M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ2001, 323, 42–46
39. Lo, C.K.; Mertz, D.; Loeb, M. Newcastle-ottawa scale: Comparing reviewers’ to authors’ assessments. BMC Med. Res. Methodol.2014, 14, 45
40. Cohen, J. Statistical Power Analysis of the Behavioural Sciences; Lawrence Erlbaum Associates: Hillsdale, NJ, USA, 1988
41. Panidis, D.; Balaris, C.; Farmakiotis, D.; Rousso, D.; Kourtis, A.; Balaris, V.; Katsikis, I.; Zournatzi, V.; Diamanti-Kandarakis, E. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin. Chem.2005, 51, 1691–1697
42. Hedges, L.V.; Olkin, I. Statistical Methods for Meta-Analysis; Academic Press: Orlando, FL, USA, 1985
43. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol.2005, 5, 13
44. Rupinski, M.T.; Dunlap, W.P. Approximating pearson product-moment correlations from kendall’s tau and spearman’s rho. Educ. Psychol. Meas.1996, 56, 429–429
45. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560
46. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials1986, 7, 177–188
47. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ1997, 315, 629–634
48. Hassan, N.E.; El-Orabi, H.A.; Eid, Y.M.; Mohammed, N.R. Effect of 25-hydroxyvitamin D on metabolic parameters and insulin resistance in patients with polycystic ovarian syndrome. Middle East Fertil. Soc. J.2012, 17, 176
49. Zawadski, J.K.; Dunaif, A. In The Polycystic Ovary Syndrome; Givens, J.H.F., Merriman, G., Eds.; Blackwell Scientific: Cambridge, MA, USA, 1992; pp. 377–384
50. Savastano, S.; Valentino, R.; di Somma, C.; Orio, F.; Pivonello, C.; Passaretti, F.; Brancato, V.; Formisano, P.; Colao, A.; Beguinot, F.; et al. Serum 25-hydroxyvitamin D levels, phosphoprotein enriched in diabetes gene product (ped/pea-15) and leptin-to-adiponectin ratio in women with pcos. Nutr. Metab.2011, 8, 84
51. Nestler, J.E.; Reilly, E.R.; Cheang, K.I.; Bachmann, L.M.; Downs, R.W. A pilot study: Effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. Trans. Am. Clin. Climatol. Assoc.2012, 123, 209–219
52. Mahmoudi, T.; Gourabi, H.; Ashrafi, M.; Yazdi, R.S.; Ezabadi, Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil. Steril.2010, 93, 1208–1214
53. Li, H.W.; Brereton, R.E.; Anderson, R.A.; Wallace, A.M.; Ho, C.K. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metab. Clin. Exp.2011, 60, 1475–1481
54. Lin, M.W.; Tsai, S.J.; Chou, P.Y.; Huang, M.F.; Sun, H.S.; Wu, M.H. Vitamin D receptor 1a promotor −1521 g/c and −1012 a/g polymorphisms in polycystic ovary syndrome. Taiwan J. Obstet. Gynecol.2012, 51, 565–571
55. Mazloomi, S.; Sharifi, F.; Hajihosseini, R.; Kalantari, S.; Mazloomzadeh, S. Association between hypoadiponectinemia and low serum concentrations of calcium and vitamin D in women with polycystic ovary syndrome. ISRN Endocrinol. 2012, 2012, 949427
56. Tsakova, A.D.; Gateva, A.T.; Kamenov, Z.A. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int. J. Vitam. Nutr. Res.2012, 82, 399–404
57. El-Shal, A.S.; Shalaby, S.M.; Aly, N.M.; Rashad, N.M.; Abdelaziz, A.M. Genetic variation in the vitamin D receptor gene and vitamin D serum levels in egyptian women with polycystic ovary syndrome. Mol. Biol. Rep.2013, 40, 6063–6073
58. Guducu, N.; Gormus, U.; Kutay, S.S.; Kavak, Z.N.; Dunder, I. 25-hydroxyvitamin D levels are related to hyperinsulinemia in polycystic ovary syndrome. Gynecol. Endocrinol. 2014, 1–4
59. Ghadimi, R.; Esmaeilzadeh, S.; Firoozpour, M.; Ahmadi, A. Does vitamin D status correlate with clinical and biochemical features of polycystic ovarysyndrome in high school girls? Casp. J. Intern. Med.2014, 5, 202–208
60. Sahin, S.; Eroglu, M.; Selcuk, S.; Turkgeldi, L.; Kozali, S.; Davutoglu, S.; Muhcu, M. Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome. Eur. Rev. Med. Pharmacol. Sci.2014, 18, 2851–2856
61. Patra, S.K.; Nasrat, H.; Goswami, B.; Jain, A. Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome. Diabetes Metab. Syndr.2012, 6, 146–149
62. Bhattacharya, S.M.; Jha, A. Association of vitamin D3 deficiency with clinical and biochemical parameters in indian women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet.2013, 123, 74–75
63. Velija-Asimi, Z. Evaluation of the association of vitamin D deficiency with gonadotropins and sex hormone in obese and non-obese women with polycystic ovary syndrome. Med. Glas.2014, 11, 170–176
64. Hahn, S.; Haselhorst, U.; Tan, S.; Quadbeck, B.; Schmidt, M.; Roesler, S.; Kimmig, R.; Mann, K.; Janssen, O.E. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes2006, 114, 577–583
65. Yildizhan, R.; Kurdoglu, M.; Adali, E.; Kolusari, A.; Yildizhan, B.; Sahin, H.G.; Kamaci, M. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch. Gynecol. Obstet.2009, 280, 559–563
66. Bonakdaran, S.; Khorasani, Z.M.; Davachi, B.; Khorasani, J.M. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in pcos patients: A randomized placebo-controlled clinical trial. Iran. J. Reprod. Med.2012, 10, 465–472
67. Kozakowski, J.; Kapuscinska, R.; Zgliczynski, W. Associations of vitamin D concentration with metabolic and hormonal indices in women with polycystic ovary syndrome presenting abdominal and gynoidal type of obesity. Ginekol. Pol.2014, 85, 765–770
68. Kotsa, K.; Yavropoulou, M.P.; Anastasiou, O.; Yovos, J.G. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil. Steril.2009, 92, 1053–1058
69. Selimoglu, H.; Duran, C.; Kiyici, S.; Ersoy, C.; Guclu, M.; Ozkaya, G.; Tuncel, E.; Erturk, E.; Imamoglu, S. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J. Endocrinol. Investig.2010, 33, 234–238
70. Wehr, E.; Pieber, T.R.; Obermayer-Pietsch, B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: A pilot study. J. Endocrinol. Investig. 2011, 34, 757–763
71. Ardabili, H.R.; Gargari, B.P.; Farzadi, L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr. Res.2012, 32, 195–201
72. Pal, L.; Berry, A.; Coraluzzi, L.; Kustan, E.; Danton, C.; Shaw, J.; Taylor, H. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol. Endocrinol.2012, 28, 965–968
73. Rahimi-Ardabili, H.; Pourghassem Gargari, B.; Farzadi, L. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. J. Endocrinol. Investig.2013, 36, 28–32
74. Asemi, Z.; Foroozanfard, F.; Hashemi, T.; Bahmani, F.; Jamilian, M.; Esmaillzadeh, A. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clin. Nutr. 2014, doi:10.1016/j.clnu.2014.09.015
75. Raja-Khan, N.; Shah, J.; Stetter, C.M.; Lott, M.E.; Kunselman, A.R.; Dodson, W.C.; Legro, R.S. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: A randomized, controlled pilot trial. Fertil. Steril. 2014, 101, 1740–1746
76. Tehrani, H.G.; Mostajeran, F.; Shahsavari, S. The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with poly cystic ovarian syndrome. J. Res. Med. Sci.2014, 19, 875–880
77. Carmina, E.; Lobo, R.A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil. Steril.2004, 82, 661–665
78. Dunaif, A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr. Rev. 1997, 18, 774–800
79. Schachter, M.; Raziel, A.; Friedler, S.; Strassburger, D.; Bern, O.; Ron-El, R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum. Reprod.2003, 18, 721–727
80. Moran, L.J.; Misso, M.L.; Wild, R.A.; Norman, R.J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. Update 2010, 16, 347–363
81. Huang, A.; Brennan, K.; Azziz, R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the national institutes of health 1990 criteria. Fertil. Steril.2010, 93, 1938–1941
82. Bourlon, P.M.; Billaudel, B.; Faure-Dussert, A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J. Endocrinol.1999, 160, 87–95
83. Liu, E.; Meigs, J.B.; Pittas, A.G.; McKeown, N.M.; Economos, C.D.; Booth, S.L.; Jacques, P.F. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J. Nutr.2009, 139, 329–334
84. Mattila, C.; Knekt, P.; Mannisto, S.; Rissanen, H.; Laaksonen, M.A.; Montonen, J.; Reunanen, A. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care2007, 30, 2569–2570
85. Ortlepp, J.R.; Metrikat, J.; Albrecht, M.; von Korff, A.; Hanrath, P.; Hoffmann, R. The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabetic Med. 2003, 20, 451–454
86. Scragg, R.; Sowers, M.; Bell, C.; Third National, H.; Nutrition Examination, S. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care 2004, 27, 2813–2818
87. Zeitz, U.; Weber, K.; Soegiarto, D.W.; Wolf, E.; Balling, R.; Erben, R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003, 17, 509–511.